Skip to main content

Caboxen 20 mg & 80 mg ( Cabozantinib)

Caboxen is identified on this website as a product containing cabozantinib in stated strengths of 20 mg and 80 mg. Cabozantinib is a targeted anticancer medicine belonging to the multi-target receptor tyrosine kinase inhibitor class. It is used in selected cancer treatment settings according to the formulation and applicable regulatory authorization.

Understanding the manufacturer of Caboxen is an important part of responsible pharmaceutical product identification. However, the specific company manufacturing Caboxen has not been independently established from the available product information. Therefore, this website does not attribute Caboxen to a pharmaceutical company without supporting documentation.

Manufacturer identification should be based on the actual medicine packaging, official product documentation, marketing authorization records or information issued by the responsible pharmaceutical company.

Who Manufactures Caboxen?

The specific manufacturer of Caboxen requires product-level verification.

The brand name alone is not sufficient evidence to identify the company responsible for manufacturing the medicine. Different pharmaceutical companies may produce medicines containing the same active ingredient under different brand names.

The following information is currently identified:

Product attributeInformation
Brand nameCaboxen
Generic medicineCabozantinib
Stated strengths20 mg and 80 mg
Therapeutic categoryAntineoplastic medicine
Pharmacological classMulti-target tyrosine kinase inhibitor
Manufacturer–
Brand owner–
Marketing authorization holder–
Country of manufacture–

This distinction is important because the company that originally developed cabozantinib may not manufacture every product containing the ingredient.

Who Developed Cabozantinib?

Cabozantinib is associated with the pharmaceutical development program of Exelixis, a biotechnology company involved in the discovery and development of targeted cancer medicines.

The medicine became commercially available through established branded products, including CABOMETYX and COMETRIQ.

The FDA’s official labeling identifies Exelixis, Inc. in connection with these reference products.

However, this does not establish that Exelixis manufactures Caboxen.

The originator or reference-product company should not automatically be identified as the manufacturer of a separately branded pharmaceutical product.

Understanding the Relationship Between Cabozantinib and Its Brands

Cabozantinib is the generic active ingredient. Different products containing cabozantinib can have different brand names, strengths, dosage forms, manufacturers and regulatory histories.

Two established reference products illustrate this distinction.

CABOMETYX

CABOMETYX contains cabozantinib in tablet form.

Its current U.S. labeling identifies 20 mg, 40 mg and 60 mg tablets. It has recognized indications involving selected cases of renal cell carcinoma, hepatocellular carcinoma, differentiated thyroid cancer and pancreatic or extra-pancreatic neuroendocrine tumors.

COMETRIQ

COMETRIQ contains cabozantinib in capsule form.

Its U.S. prescribing information identifies 20 mg and 80 mg capsules and specifies its use for progressive metastatic medullary thyroid cancer.

The two formulations are not bioequivalent and must not be interchanged.

This is especially important when examining Caboxen because its stated 20 mg and 80 mg strengths resemble the reference capsule strengths. Nevertheless, the formulation of Caboxen must be verified independently.

Manufacturer, Brand Owner and Marketing Authorization Holder

These pharmaceutical terms describe different responsibilities.

Manufacturer: The company or manufacturing site responsible for producing the medicine. Depending on the arrangement, manufacturing activities may be performed by a contracted organization.

Brand owner: The company or legal entity associated with ownership of the commercial brand name.

Marketing authorization holder: The legal entity responsible for the marketing authorization of a medicine in a particular jurisdiction.

Distributor: The organization responsible for distributing a medicine through an appropriate supply chain.

Supplier: A commercial party that provides a medicine to another business or customer.

Original developer: The company or organization responsible for discovering or developing the active pharmaceutical ingredient or original medicine.

One company may perform several of these roles, while other pharmaceutical arrangements involve multiple independent organizations.

For this reason, the identity of the original cabozantinib developer does not establish the manufacturer of Caboxen.

Importance of Pharmaceutical Manufacturing Standards

The manufacturing of anticancer medicines requires appropriate quality systems and regulatory oversight.

Manufacturing quality is important because differences in product quality can affect the identity, strength, purity, stability and consistency of a pharmaceutical preparation.

Responsible pharmaceutical manufacturing processes generally address:

  • Raw material identification and quality.
  • Active pharmaceutical ingredient specifications.
  • Manufacturing procedures.
  • Quality control testing.
  • Finished-product testing.
  • Packaging and labeling.
  • Batch documentation.
  • Storage conditions.
  • Distribution controls.
  • Product traceability.

Good Manufacturing Practice (GMP) requirements are established by relevant regulatory authorities. The specific manufacturing facility and its applicable certifications should be verified rather than assumed.

No particular GMP certification, production facility or manufacturing quality claim is attributed to Caboxen on this website without documentary evidence.

How to Identify the Caboxen Manufacturer

Visitors and healthcare professionals reviewing Caboxen should examine the original packaging and accompanying product leaflet.

Important information includes:

  1. The full brand name.
  2. The generic ingredient, cabozantinib.
  3. The stated strength.
  4. The dosage form.
  5. The manufacturer’s legal name.
  6. The manufacturing address, where supplied.
  7. The marketing authorization holder.
  8. The country-specific registration details.
  9. The batch or lot number.
  10. The expiry date.

If the packaging identifies a manufacturer, the information should be compared with available official company and regulatory records.

A distributor or importer should not be incorrectly described as the manufacturer.

Product Authenticity and Supply Chain

Cabozantinib is a prescription anticancer medicine, making legitimate pharmaceutical sourcing particularly important.

Counterfeit or falsified medicines may contain incorrect ingredients, inappropriate strengths, contaminants or no active ingredient.

A responsible verification process should consider the complete supply chain rather than relying only on a brand logo or packaging appearance.

Patients should obtain prescription medicines through legally authorized channels and seek assistance from a pharmacist or healthcare professional if product identity is uncertain.

Manufacturer Information Disclaimer

The manufacturer of the specific Caboxen product remains subject to independent verification.

The website distinguishes the established history of cabozantinib and its reference products from the unverified corporate identity of Caboxen.

It does not claim that Caboxen is manufactured by Exelixis or that it is identical to CABOMETYX or COMETRIQ.

For accurate product identification, the actual Caboxen packaging and official documentation should be consulted.